<DOC>
	<DOCNO>NCT02418767</DOCNO>
	<brief_summary>The study Phase 1 , randomize , double-blind , vehicle-controlled , single-dose , three dose level study healthy Caucasian Japanese male volunteer . Following 4-week screening period , eligible male subject stratify ethnic group randomize one six group . On dose day , designate Day 1 , subject receive single SC injection study medication accord group allocation follow month safety monitoring .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Long Acting Human Growth Hormone ( hGH ) Product ( MOD-4023 ) Healthy Caucasian Japanese Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<criteria>1 . Healthy male volunteer , 18 45 year age ( inclusive ) . 2 . Body Mass Index ( BMI ) 18 30 kg/m2 ( inclusive ) weigh least 55 kg . 3 . Subjects generally good health opinion investigator determine medical history , vital sign physical examination . 4 . Blood pressure heart rate within normal limit . 5 . Electrocardiogram ( ECG ) clinically significant abnormality record screen visit ( 28 day dose ) dose day ( drug administration ) . 6 . Negative HIV , hepatitis B hepatitis C serology test screen 7 . No clinically significant abnormality complete blood count ( CBC ) , international normalize ratio ( INR ) , chemistry lab test ( liver renal function ) urinalysis screen . 8 . No history alcohol drug abuse within 1 year screening . Negative urine drugsofabuse ( DOA ) screen admission . Negative breath alcohol admission . 9 . Subjects must agree use medically accept form contraception dose day 12 week drug administration . 10 . Subjects must able understand requirement study must willing comply requirement study provide write informed consent participate study . 1 . History significant neurological ( include history seizure EEG abnormality ) , renal , cardiovascular ( include know structural cardiac abnormality hypertension ) , respiratory ( asthma ) , endocrinological , gastrointestinal , hematopoietic disease , neoplasm , psychological ( marked anxiety , tension agitation ) clinically significant medical disorder , investigator 's judgment contraindicate administration study medication . 2 . Known allergy growth hormone constituents ingredient component vehicle . 3 . Adherence ( whatever reason ) abnormal diet ( include dietary restriction , e.g . low fat , lactosefree , low sodium , high protein , glutenfree , organic , etc . ) 4 week prior study , subject recent significant change body weight . 4 . Use prescription overthecounter ( OTC ) medication , include vitamin herbal dietary supplement within 14 day prior dose . Brief use OTC medication symptomatic relief pain 24 hour prior 48 hour study drug administration may allow per discretion medical monitor . 5 . Subjects receive vaccine within 4 week prior study drug administration . 6 . Subjects donate blood receive blood plasma derivative one month precede sign consent form . 7 . Systemic corticosteroid replacement dos within 3 month study entry ( temporary adjustment glucocorticoid , appropriate , acceptable ) 8 . Anabolic steroid gonadal steroid replacement therapy within 2 month study entry 9 . Participation another clinical trial drug within one month sign consent form ( calculate previous study 's last dosing date ) . 10 . Subjects inability communicate well investigator clinic staff [ i.e. , language problem ( except Japanese speaker ) , poor mental development impair cerebral function ] . 11 . Subjects acute medical situation ( e.g . acute infection ) within 48 hour study start , consider significance Principal Investigator . Use investigational product ( within 30 day screen visit ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>